PPP2R1A mutations portend improved survival after cancer immunotherapy

Mitsutake Yano & Amir A. Jazaeri et al. · 2025

19Citations
Immune checkpoint blockade (ICB) therapy is effective against many cancers, although resistance remains a major issue and new strategies are needed to improve clinical outcomes
Links
DOIPubMed
Journal
Unknown Journal
TL;DR

Inactivating PPP2R1A mutations correlate with better survival after immune checkpoint blockade in patients with ovarian clear cell carcinoma, suggesting that targeting the phosphatase 2A (PP2A) pathway may represent an effective startegy for improving responses to immunotherapy.

AI-generated by Semantic Scholar

Institutions
Oita UniversityThe University Of Texas Md Anderson Cancer CenterIndiana University School Of MedicineThe University Of Texas SystemPennsylvania Department Of Environmental ProtectionUnknown InstitutionUniversity Of California San DiegoUniversity Of Houston
Authors
Mitsutake Yano, Minghao Dang, Annalyn Welp, Manoj Chelvanambi, Matthew Lastrapes, Luis J. Montaner, Jiakai Hou, Jinsong Liu, R. Tyler Hillman, Shannon N. Westin, Anil K. Sood, Jennifer A. Wargo, Weiyi Peng, Rugang Zhang, Linghua Wang, Amir A. Jazaeri
Funding
Training of Academic Gynecologic OncologistsCancer Center Support GrantSignaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancerHealth Services Career Development: Improving Medical Decisions in Ovarian CancerAnimal Shared ResourceSynthetic lethality based combination approaches to ARID1A mutation in ovarian cancerGeneral Clinical Research CenterMetabolic basis of ARID1A-mutated ovarian cancerProject 2: Combination PARPi-BETi to Overcome PARPi ResistanceDevelopmental Research ProgramNCI NIH HHS Grant L30 CA123720Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancerNovaSeq6000Regulation of tumor recurrence by stress activated neutrophilsTumor cell lineage diversity and composition in gastric cancer progression and therapy resistanceDevelopment of the MasSpec Pen Technology to Guide Surgical Decisions in the Care for Patients with Ovarian CancerCenter for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D)